Search
Highlights from the SWG
SWG Session at EHA2023ELN-EHA SWG for CML: CML: modelling the futureChairJane Apperley (United Kingdom)
Topics and presenters
Identifying new targets for BCR::ABL1 inhibition: Oliver Hantschel (Germany). Dissecting phylogenetic trees in CML: Aleksandra Kamizela (United Kingdom).
EHA-TSH Hematology Tutorial
EHA is joining the Turkish Society of Hematology (TSH) to organize the EHA-TSH Hematology Tutorial on T Cell Lymphomas. Date: June 29-30, 2024
Location: Ankara, Türkiye
Format: In-Person
Target audienceHematology fellows from Türkiye.
EHA Guidelines on Recommendations for Pregnancy in Rare Inherited Anemias
EHA and the Scientific Working Group on Red Cells and Iron organized the first online workshop on the EHA Guidelines: “Recommendations for Pregnancy in Rare Inherited Anemias”.
Read moreEHA-SHRC Hematology Tutorial on Thalassemia
Dates: May 10-11, 2018
Location: Shiraz, Iran
Chairs: M Karimi, MD Cappellini & A Taher
EHA in close collaboration with Shiraz Hematology Research Center and the Shiraz Medical Center, endorsed by the Iranian Pediatric Hematology Oncology Society, organize a two day tutorial on “Thalassemia”.…
EHA-SWG Scientific Meeting on Red Cell and Iron Metabolism Defects: From Basic Science to Clinical Case Application
Dates: October 12-14, 2023
Location: Budapest, Hungary
Chairs: A Taher & A Iolascon
Collaborating SWG: EHA Specialized Working Group on Red Cells and Iron
Registration is closed
RegistrationRegistration is closed. Visit this page for more information.
Overview of EHA's Hemoglobinopathies Initiatives
The EHA Topics-in-Focus Hemoglobinopathies Program (focus on Sickle Cell Disease) aims to expand awareness and education about these increasingly common genetic diseases in Europe, among healthcare professionals, patients and the general population.
Read moreMajor bleeding in patients on treatment with NOACs or VKAs in real-life: clinical presentation, management and outcome
Major bleeding in patients on treatment with NOACs or VKAs in real-life: clinical presentation, management and outcome
Limited data are available on major bleeding (MB) occurring during treatment with vitamin K (VKAs) or non-vitamin K antagonist oral anticoagulants (NOACs) outside clinical…
Treatment of acute lymphoblastic leukemia by activation of patient's immune cells by a bispecific antibody.
Abstract S722
Acute lymphoblastic leukemia (ALL) is a rare type of blood cancer which is mainly treated by intensive chemotherapy.
- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- 134
- 135
- 136
- 137
- 138
- 139
- »